Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Vokó, Zoltán ^a,b,c   Nagyjánosi, László ^b   Kaló, Zoltán ^a,b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b Syreon Research Institute   (Hungary)

^c National Institute for Health Development   (Hungary)

Author keywords

Cervarix; Cervical cancer; Cost effectiveness; Human papillomavirus; Hungary; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUNGARY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PROBABILITY; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; HUNGARY; MARKOV CHAINS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84867901529     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-924     Document Type: Article

References (43)

1. US Preventive Services Task Force, Recommendations on screening for cervical cancer http://www.uspreventiveservicestaskforce.org/uspstf11/ cervcancer/cervcancerrs.htm
2. Partridge EE; Gynecologic Cancer Advisory Group, Garcia F: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, CA Cancer J Clin 2007 57 7 28 10.3322/canjclin.57.1.7 17237032 (Pubitemid 46148088)
3. Cervical cytology screening. American College of Obstetricians and Gynecologists (ACOG), ACOG Practice Bull 2009 109
4. World Health Organization, Cervical cancer, human papillomavirus (HPV), and HPV vaccines-Key points for policy-makers and health professionals Geneva: WHO 2010
5. Organized, nationwide cervical screening programme in Hungary. Boncz I, Sebestyén A, Ember I, Gynecol Oncol 2007 106 272 273 10.1016/j.ygyno. 2007.03.017 17467779 (Pubitemid 46908744)
6. Cervical screening in Hungary: why does the «English model» work but the «Hungarian model» does not? Kovács A, Döbrössy L, Budai A, Boncz I, Cornides A, Eur J Gynaecol Oncol 2008 29 5 9 18386456 (Pubitemid 351344754)
7. Modeling cost-effectiveness of different scenarios of cervical screening in Hungary. Vokó Z, Nagyjánosi L, Margitai B, Kövi R, Tóth Z, László D, Kaló Z, Value Health 2012 15 39 45 10.1016/j.jval.2011.10.003 22264970
8. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA, Popul Health Metr 2007 5 11 10.1186/1478-7954-5-11 17967185 (Pubitemid 351167796)
9. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA, An individual-based stochastic microsimulation of human papillomavirus and cervical cancer in the United States Model structure, parameterization, calibration, evaluation, screening and vaccination strategies: Supplemental technical information 2009 Available from: http://www.pophealthmetrics.com/ content/5/1/11/additional/. [Accessed March 3, 2009]
10. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Szende A, Mogyorósy Z, Muszbek N, Nagy J, Pallos G, Dózsa C, Eur J Health Econ 2002 3 196 206 10.1007/s10198-002-0109-6 (Pubitemid 36406341)
11. A méhnyakszrés részvételi mutatói Magyarországon (in Hungarian) [The coverage of cervical screening in Hungary]. Boncz I, Sebestyén A, Döbrössy L, Kovács A, Budai A, Székely T, Orv Hetil 2007 148 46 2177 82 10.1556/OH.2007.28956 17988975 (Pubitemid 350200381)
12. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Munoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ, Int J Cancer 2004 11 278 285 (Pubitemid 38924707)
13. European Medicine Agency, CHMP variation assessment report Type II variation EMEA/H/C/000721/II/0011 2010 http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Assessment-Report-Variation/human/000721/WC500098066.pdf
14. Long-term efficacy of human papillomavirus vaccination. Ault KA, Gynecol Oncol 2007 107 2 Suppl 1 27 30
15. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A, GlaxoSmithKline Vaccine HPV-007 Study Group, Lancet 2009 374 1975 1985 19962185
16. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA, Vaccine 2007 25 4324 4333 10.1016/j.vaccine.2007.02.069 17445955 (Pubitemid 46635934)
17. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P, Gynecol Oncol 2009 115 3 Suppl 1 6 19217149
18. OECD Statextracts, http://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP
19. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W, Vaccine 2010 28 3379 3384 10.1016/j.vaccine.2010.02.080 20197141
20. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J, Int J Cancer 2009 124 970 978 10.1002/ijc.24000 19035448
21. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. de Kok IM, van Ballegooijen M, Habbema JD, J Natl Cancer Inst 2009 101 1083 1092 10.1093/jnci/djp183 19571256
22. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E, J Natl Cancer Inst 2004 96 604 615 10.1093/jnci/djh104 15100338 (Pubitemid 38584984)
23. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, Hahl J, J Med Econ 2010 13 284 294 10.3111/13696998.2010.485951 20482244
24. Cost-effectiveness of a potential vaccine for human papillomavirus. Sanders GD, Taira AV, Emerg Infect Dis 2003 9 37 48 10.3201/eid0901.020168 12533280 (Pubitemid 36110201)
25. Cost-effectiveness analysis of HPV vaccination alongside cervical screening programme in Slovenia. Obradovic M, Mrhar A, Kos M, Eur J Public Health 2010 20 415 421 10.1093/eurpub/ckp208 20624834
26. Evaluating human papillomavirus vaccination programs. Taira AV, Neukermans CP, Sanders GD, Emerg Infect Dis 2004 10 1915 1923 10.3201/eid1011.040222 15550200 (Pubitemid 39458555)
27. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM, Vaccine 2007 26 128 139 10.1016/j.vaccine.2007.10.056 18055075 (Pubitemid 350218187)
28. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V, Int J Technol Assess Health Care 2008 24 10 19 18218164 (Pubitemid 351158538)
29. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Brisson M, Van de Velde N, De Wals P, Boily MC, Vaccine 2007 25 5399 5408 10.1016/j.vaccine.2007.04.086 17561316 (Pubitemid 46977529)
30. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical screening programme in Switzerland. Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S, Curr Med Res Opin 2008 24 1473 1483 10.1185/030079908X297826 18413014 (Pubitemid 351741581)
31. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical screening Program. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G, Sex Health 2007 4 165 175 10.1071/SH07043 17931529 (Pubitemid 47339645)
32. Cost-utility analysis of vaccination against HPV in Israel. Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J, Vaccine 2007 25 6677 6691 10.1016/j.vaccine.2007.07.018 17706844 (Pubitemid 47337133)
33. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Olsen J, Jepsen MR, Int J Technol Assess Health Care 2010 26 183 191 10.1017/S0266462310000085 20392322
34. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Dasbach EJ, Largeron N, Elbasha EH, Expert Rev Pharmacoecon Outcomes Res 2008 8 491 500 10.1586/14737167.8.5.491 20528334
35. Adding a quadrivalent human papillomavirus vaccine to the UK cervical screening programme: A cost-effectiveness analysis. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER, Cost Eff Resour Alloc 2008 6 4 10.1186/1478-7547-6-4 18279515 (Pubitemid 351513973)
36. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Dee A, Howell F, Eur J Public Health 2010 20 213 9 10.1093/eurpub/ckp141 19864366
37. Cost-effectiveness analyses of human papillomavirus vaccination. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR, Lancet Infect Dis 2007 7 289 96 10.1016/S1473-3099(07)70083-X 17376386 (Pubitemid 46414076)
38. Structural differences among cost-effectiveness models of human papillomavirus vaccines. Insinga RP, Dasbach EJ, Elbasha EH, Expert Rev Vaccines 2008 7 895 913 10.1586/14760584.7.7.895 18767941
39. Modeling cervical cancer prevention in developed countries. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ, Vaccine 2008 26 Suppl 10 76 86 18847560
40. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Van de Velde N, Brisson M, Boily MC, Vaccine 2010 28 5473 5484 10.1016/j.vaccine.2010.05.056 20573580
41. Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion. Postma MJ, Vaccine 2010 28 873 874 10.1016/j.vaccine.2009.10.109 19896454
42. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J, Value Health 2009 12 409 418 10.1111/j.1524-4733.2008.00489.x 19900249
43. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH, J Med Econ 2010 13 110 118 10.3111/13696990903546013 20085477